<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-20</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-20</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>123</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯å®ç°è¡¨è§‚åŸºå› ç»„ç»´æŒåŠ¨æ€è¿‡ç¨‹é‡æ„ï¼›ä¸­å›½ç§‘å­¦å®¶å‘æ˜é€šç”¨å‹æŠ—ç™Œå…ç–«ç–—æ³•ï¼Œè¯±å¯¼ç‰¹å¼‚æ€§Tç»†èƒæ€ç­ç™Œç»†èƒã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è§£æä»£è°¢å¼‚å¸¸ä¸è¡¨è§‚é—ä¼ äº¤å‰è°ƒæ§å¤šå›Šåµå·¢ç»¼åˆå¾ï¼ˆPCOSï¼‰æ–°æœºåˆ¶ï¼Œå…³æ³¨PKM2ä»‹å¯¼çš„ç»„è›‹ç™½ä¹³é…¸åŒ–ã€‚<br />
- æ­ç¤ºè‚¿ç˜¤çªå˜å¦‚ä½•å¼•çˆ†å…ç–«æ²»ç–—ï¼Œä»¥åŠç±»æ½˜æ°ç»†èƒè½¬åˆ†åŒ–é©±åŠ¨ç»“ç›´è‚ ç™Œå¯¹é¶å‘æ²»ç–—çš„è€è¯æ€§ã€‚<br />
- æ¢ç´¢è‚ é“å¾®ç”Ÿç‰©ç»„ä¸ç–¾ç—…ï¼ˆå¦‚è‡ªé—­ç—‡ã€è‚¥èƒ–ï¼‰çš„å…³è”ï¼Œä»¥åŠåŠ¨ç‰©ä»æµ·æ´‹èµ°å‘é™†åœ°çš„åŸºå› ç»„ç§˜å¯†ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆå•ç»†èƒå¤šç»„å­¦ï¼ˆDNAç”²åŸºåŒ–ã€ç»„è›‹ç™½ä¿®é¥°ã€RNAæµ‹åºã€ç©ºè½¬ã€ä»£è°¢ç»„ï¼‰æŠ€æœ¯ï¼Œå®ç°é«˜ç²¾åº¦è¡¨è§‚åŸºå› ç»„åˆ†æå’ŒåŠ¨æ€è¿‡ç¨‹é‡æ„ã€‚<br />
- å¼€å‘æ–°å‹æŠ—ç™Œå…ç–«ç–—æ³•ï¼Œåˆ©ç”¨ç™Œç»†èƒè¡¨è¾¾å¼‚æºæŠ—åŸè¯±å¯¼ç‰¹å¼‚æ€§Tç»†èƒåº”ç­”ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºèƒ¶è´¨æ¯ç»†èƒç˜¤ä¸­å…·æœ‰æŠ—è‚¿ç˜¤æ´»æ€§çš„PKCÎ´è¡¨è¾¾å°èƒ¶è´¨ç»†èƒï¼›SCUBE3é¶å‘ç–—æ³•æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿ä¸è½¬ç§»ï¼Œè¯±å¯¼æŠ—è‚¿ç˜¤å…ç–«ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«ï¼šæ¢ç´¢å°èƒ¶è´¨ç»†èƒã€CAR-Tç»†èƒã€NKç»†èƒåœ¨è‚¿ç˜¤æ²»ç–—ä¸­çš„ä½œç”¨ï¼›ç ”ç©¶å†…æºæ€§é€†è½¬å½•ç—…æ¯’ä¸Tç»†èƒåˆ†åŒ–ã€è‡ªèº«å…ç–«ç–¾ç—…ï¼ˆå¦‚SLEï¼‰çš„å…³ç³»ã€‚<br />
- ä¿¡å·é€šè·¯ä¸ä»£è°¢ï¼šç ”ç©¶DPP4å¯¹KRASçªå˜è‚ºç™Œå…ç–«çš„ä¿ƒè¿›ä½œç”¨ï¼›é˜æ˜FAM20Cåœ¨è‚¥èƒ–å’Œèƒ°å²›ç´ æŠµæŠ—ä¸­çš„æœºåˆ¶ï¼›æ­ç¤ºEfferocytosiså¯¹éª¨é«“ç»†èƒä»£è°¢åŠç‚ç—‡çš„å½±å“ã€‚<br />
- è‚¿ç˜¤æ²»ç–—ç­–ç•¥ï¼šå¼€å‘é¶å‘SCUBE3ã€MYB::NFIBèåˆè›‹ç™½ã€KRAS G-quadruplexçš„å°åˆ†å­è¯ç‰©ï¼›è¯„ä¼°å…¨ç¯åŒ–ä¾èµ–æ€§æ¿€é…¶æŠ‘åˆ¶å‰‚åœ¨è…ºæ ·å›Šæ€§ç™Œä¸­çš„æ²»ç–—æ½œåŠ›ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç©ºé—´è½¬å½•ç»„å­¦ï¼ˆSpatial Transcriptomicsï¼‰åº”ç”¨äºè‚¿ç˜¤å¾®ç¯å¢ƒå’Œç»„ç»‡å‘è‚²ç ”ç©¶ã€‚<br />
- Ribo-liteæ–¹æ³•å®ç°ä½è¾“å…¥é‡AMLç»†èƒçš„è½¬å½•ç»„å’Œç¿»è¯‘ç»„è”åˆåˆ†æã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ­ç¤ºè‚¿ç˜¤èµ·å§‹é˜¶æ®µå·¨å™¬ç»†èƒæåŒ–è°ƒæ§å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒï¼Œä»¥åŠçº¿ç²’ä½“è½¬ç§»æŒ½æ•‘å‘¼å¸æ”¯æŒè‚¿ç˜¤è¿›å±•çš„æ–°æœºåˆ¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒå…ç–«æŠ‘åˆ¶æœºåˆ¶ï¼šç ”ç©¶å·¨å™¬ç»†èƒåœ¨è‚¿ç˜¤èµ·å§‹é˜¶æ®µçš„æåŒ–å¦‚ä½•å½¢æˆå…ç–«æŠ‘åˆ¶æ€§â€œå†·â€è‚¿ç˜¤å¾®ç¯å¢ƒã€‚<br />
- ç™Œç—‡å…ç–«æ²»ç–—ç­–ç•¥ï¼šæ¢ç´¢åŒç‰¹å¼‚æ€§æŠ—ä½“ä¸çº³ç±³æŠ€æœ¯ç»“åˆï¼Œæå‡ç™Œç—‡å…ç–«æ²»ç–—æ•ˆç‡å¹¶é™ä½æ¯’æ€§ã€‚<br />
- ç™Œç—‡è€è¯æ€§æœºåˆ¶ï¼šé€šè¿‡CRISPR-Cas9ç­›æŸ¥ï¼Œè¯†åˆ«èƒ°è…ºç™Œä¸­KRASæŠ‘åˆ¶å‰‚çš„è€è¯æœºåˆ¶ã€‚<br />
- è‚¿ç˜¤ç»†èƒä»£è°¢ä¸ç”Ÿé•¿ï¼šç ”ç©¶çº¿ç²’ä½“è½¬ç§»å¦‚ä½•æŒ½æ•‘çº¿ç²’ä½“DNAç¼ºä¹ç™Œç»†èƒçš„å‘¼å¸åŠŸèƒ½ï¼Œæ”¯æŒå…¶è‚¿ç˜¤ç”Ÿé•¿ã€‚<br />
- ç™Œç—‡è½¬ç§»é©±åŠ¨å› å­ï¼šé‰´å®šGRPRè¯±å¯¼çš„FAM135Aè¡¨è¾¾åœ¨å‰åˆ—è…ºç™Œç¥ç»å‘¨æµ¸æ¶¦ä¸­çš„ä½œç”¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å•ç»†èƒRNAæµ‹åºï¼šç”¨äºè¡¨å¾è‚¿ç˜¤èµ·å§‹é˜¶æ®µå…ç–«å¾®ç¯å¢ƒçš„æ—¶é—´åŠ¨æ€ã€‚<br />
- CRISPR-Cas9åŸºå› ç¼–è¾‘ï¼šç”¨äºç­›æŸ¥KRASæŠ‘åˆ¶å‰‚è€è¯æœºåˆ¶ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
äºšé©¬é€Šèå­æ¯’ç´ åœ¨æ²»ç–—ä¹³è…ºç™Œæ–¹é¢å±•ç°å‡ºæ˜¾è‘—ç–—æ•ˆï¼Œæˆä¸ºå¯¹æŠ—ç™Œç—‡çš„æ–°å‹å·¥å…·ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åˆ©ç”¨èå­æ¯’ç´ ä¸­çš„åˆ†å­ç‰¹å¼‚æ€§æ€ä¼¤ä¹³è…ºç™Œç»†èƒã€‚<br />
- ç»“åˆæ”¾å°„æ€§åŒä½ç´ ã€å·¥ç¨‹è›‹ç™½å’Œäººå·¥æ™ºèƒ½å¼€å‘æ–°å‹ç™Œç—‡ç–—æ³•ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- é¦–æ¬¡å‘ç°å¹¶åº”ç”¨äºšé©¬é€Šèå­æ¯’ç´ çš„æŠ—ç™Œæ½œåŠ›ã€‚<br />
- æ•´åˆå¤šé¡¹å‰æ²¿æŠ€æœ¯ï¼ˆæ¯’ç´ ã€æ”¾å°„æ€§åŒä½ç´ ã€å·¥ç¨‹è›‹ç™½ã€AIï¼‰ä»¥å¢å¼ºç–—æ•ˆã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (31æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>å•èƒå¤šç»„ | Nat.Methods | å•ç»†èƒå¤šç»„å­¦æ£€æµ‹DNAç”²åŸºåŒ–å’Œç»„è›‹ç™½ä¿®é¥°é‡å»ºè¡¨è§‚åŸºå› ç»„ç»´æŒçš„åŠ¨æ€è¿‡ç¨‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šBioJournal Link<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šTç»†èƒã€å•ç»†èƒã€åŸºå› ç»„ã€è¡¨è§‚åŸºå› ç»„ã€ç”²åŸºåŒ–ã€ç»„è›‹ç™½<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503136&amp;idx=1&amp;sn=cb48e0e04f9e51a1bc3ad0af0f4957da" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>30+å•ç»†èƒå¤šç»„å­¦é€šè¿‡è§£æDNAç”²åŸºåŒ–ä¸ç»„è›‹ç™½ä¿®é¥°ï¼Œé‡æ„è¡¨è§‚åŸºå› ç»„ç»´æŒçš„åŠ¨æ€è¿‡ç¨‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä½œå›¾ä¸«<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€åŸºå› ç»„ã€è¡¨è§‚åŸºå› ç»„ã€ç”²åŸºåŒ–ã€ç»„è›‹ç™½<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæœ€è¿‘æœ‰å°ä¼™ä¼´åæ˜ æ”¶ä¸åˆ°æ¨é€ï¼Œå› ä¸ºå…¬ä¼—å·æ”¹äº†æ¨é€ç®—æ³•ï¼Œç°åœ¨éœ€è¦åŠ æ˜Ÿæ ‡ï¼Œå¤šç‚¹èµã€ç‚¹åœ¨çœ‹ï¼Œæ‰èƒ½å‡†æ—¶æ”¶åˆ°æ¨é€å“¦ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523442&amp;idx=1&amp;sn=0d9eb2d0ab6262731fc7aa7849d19b11" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>NBEï¼šå«ç¥¸ç™Œç»†èƒï¼ä¸­å›½ç§‘å­¦å®¶å‘æ˜é€šç”¨å‹æŠ—ç™Œå…ç–«ç–—æ³•ï¼Œè®©ç™Œç»†èƒè¡¨è¾¾ä¹™è‚ç—…æ¯’æŠ—åŸï¼Œè¯±å¯¼ç‰¹å¼‚æ€§Tç»†èƒæ€ç­ç™Œç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå¥‡ç‚¹è‚¿ç˜¤æ¢ç§˜<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€Tç»†èƒã€Bç»†èƒã€æŠ—åŸ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæå¾—ç™Œç»†èƒâ€œä¸€å¤´é›¾æ°´â€ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503519&amp;idx=1&amp;sn=d98e7f56087dc065f00aa0b1617ea245" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>é»„è·å‡¤é™¢å£«é¢†è¡”ï¼æ­ç¤ºä»£è°¢å¼‚å¸¸ä¸è¡¨è§‚é—ä¼ äº¤å‰è°ƒæ§å¤šå›Šåµå·¢ç»¼åˆå¾æ–°æœºåˆ¶ï¼ŒPKM2ä»‹å¯¼çš„ç»„è›‹ç™½ä¹³é…¸åŒ–æˆ–æ˜¯å…³é”®è‡´ç—…å› ç´ </strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šè½¬åŒ–åŒ»å­¦ç½‘<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€è¡¨è§‚é—ä¼ ã€ç»„è›‹ç™½<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šé¦–æ¬¡æ­ç¤ºä¸™é…®é…¸æ¿€é…¶M2ï¼ˆPKM2ï¼‰é€šè¿‡æ ¸æ˜“ä½ä¿ƒè¿›ç»„è›‹ç™½ä¹³é…¸åŒ–ä¿®é¥°ï¼Œé‡æ„ä¸‰ç»´åŸºå› ç»„ç»“æ„ï¼Œä»è€Œæ¿€æ´»PCOSå…³é”®è‡´ç—…åŸºå› çš„è¡¨è¾¾ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510197&amp;idx=1&amp;sn=40745a3357e49489522fca9b7c14c7b0" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>å•ç»†èƒ+ç©ºè½¬+ä»£è°¢ç»„ï¼Œå…¬å¼€æ•°æ®é›†æ‰¾å‡ºäº®ç‚¹å°±èƒ½å‘1åŒº12åˆ†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€å•ç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248620&amp;idx=8&amp;sn=14c85fcac6895fb3b909833fc2e3b523" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>Cancer Cellé‡ç£…ï¼šè‚¿ç˜¤ç«Ÿè¢«è‡ªå·±äººèƒŒåˆºï¼çªå˜å¼•çˆ†å…ç–«æ²»ç–—</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€cancerã€å…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼š10æœˆ16æ—¥ï¼ŒCancer Cellå‘è¡¨äº†å¾·å·å¤§å­¦MDå®‰å¾·æ£®ç™Œç—‡ä¸­å¿ƒPadmanee Sharmaæ•™æˆå›¢é˜Ÿçš„é‡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248620&amp;idx=3&amp;sn=5fa0f83bb7f0423626ef7f9308fc9aa0" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>è„šæœ¬æ›´æ–°--ä½ç²¾åº¦ï¼ˆvisiumã€stereo-seq bin &gt; 50ï¼‰çš„ç»†èƒé‚»åŸŸåˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒç©ºé—´äº¤å“ä¹<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šTç»†èƒã€Bç»†èƒã€Visium<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šè„šæœ¬æ›´æ–°--ä½ç²¾åº¦ï¼ˆvisiumã€stereo-seq bin &gt; 50ï¼‰çš„ç»†èƒé‚»åŸŸåˆ†æ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247499021&amp;idx=1&amp;sn=5f242254f361807de74dde90be1f129f" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>Dynamic-BW - åŠ¨æ€åŸºå› è¡¨è¾¾å›¾è°±ã€å›½å®¶ç”Ÿç‰©ä¿¡æ¯ä¸­å¿ƒã€‘</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡èœé¸Ÿå›¢<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç”Ÿç‰©ä¿¡æ¯ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šDynamic BodyMap æ˜¯ä¸€ä¸ªæ¶µç›–æ—¶é—´åºåˆ— RNA æµ‹åºæ•°æ®é›†ä¸­å¤šä¸ªç‰©ç§çš„æ•°æ®åº“ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&amp;mid=2247538150&amp;idx=1&amp;sn=78c679e0b70e921057f14b2be567ab32" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>ä»é›¶å¼€å§‹å­¦ä¹ å•ç»†èƒå…ç–«ç»„åº“ï¼ˆäºŒï¼‰ï¼šå­¦ä¼šæ·±å…¥è§£è¯»ç»“æœæ–‡ä»¶ï¼ï¼ˆæ–‡æœ«èµ ä¹¦æ´»åŠ¨ï¼‰</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡ä½œæ›²å®¶<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç§‘å­¦ï¼Œå¾ªåºæ¸è¿›çš„å•ç»†èƒå…ç–«ç»„åº“æ•™ç¨‹<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI5ODI0NzM2OQ==&amp;mid=2247491587&amp;idx=1&amp;sn=7634669271cea10c34c80c27c4a54845" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>å¡‘é€ Tç»†èƒå‘½è¿çš„å…ç–«ç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šé—²è°ˆ Immunology<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€Tç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTczNjI0OQ==&amp;mid=2247528930&amp;idx=1&amp;sn=014e1619800b30ecebd40dfef0cf0a56" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 21 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (85æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE298689 ç©ºé—´åˆ†è¾¨å•ç»†èƒåˆ†ææ­ç¤ºèƒ¶è´¨æ¯ç»†èƒç˜¤ä¸­å…·æœ‰æŠ—è‚¿ç˜¤æ´»æ€§çš„è›‹ç™½æ¿€é…¶ CÎ´ è¡¨è¾¾å°èƒ¶è´¨ç»†èƒ [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€kinaseã€single-cellã€spatialã€spatiallyã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Reza Mirzaei ; Reid McNeil ; Charlotte Dâ€™Mello ; Britney Wong ; Susobhan Sarkar ; Frank Visser ; Candice Poon ; Pinaki Bose ; Wee YongSeries Type : OtherOrganism : Mus musculusThe glioblastoma (GBM) microenvironment contains resident immune cells with intrinsic anti-tumor potential, particularly microglia. Understanding the single-cell spatial heterogeneity and interactions between immune cells and brain tumorâ€“initiating cells (BTICs) is essential for identifying therapeutic targets to reprogram immune responses and suppress BTIC growth. Using single-cell and spatial transcriptomics, we mapped immune cell populations in the GBM microenvironment and identified signaling networks mediating immuneâ€“cancer cell interactions. We discovered a previously unrecognized subset of microglia expressing protein kinase CÎ´ (PKCÎ´) with anti-tumor activity against BTICs. The presence of PKCÎ´-expressing microglia was validated in human GBM specimens. Enhancing PKCÎ´ in microglia via adeno-associated virus or niacin increased phagocytosis of patient-derived BTICs in vitro and improved survival in GBM-bearing mice. Data from The Cancer Genome Atlas (TCGA) revealed that high PKCÎ´ expression correlates with increased apoptosis, phagocytosis, and immune signaling pathways. These findings offer highlight PKCÎ´+ microglia as a promising therapeutic target in GBM.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298689" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE298688 ç©ºé—´åˆ†è¾¨å•ç»†èƒåˆ†ææ­ç¤ºèƒ¶è´¨æ¯ç»†èƒç˜¤ä¸­å…·æœ‰æŠ—è‚¿ç˜¤æ´»æ€§çš„è›‹ç™½æ¿€é…¶ CÎ´ è¡¨è¾¾å°èƒ¶è´¨ç»†èƒ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€kinaseã€single-cellã€scRNAã€spatially<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Reza Mirzaei ; Reid McNeil ; Charlotte Dâ€™Mello ; Britney Wong ; Susobhan Sarkar ; Frank Visser ; Candice Poon ; Pinaki Bose ; Wee YongSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe glioblastoma (GBM) microenvironment contains resident immune cells with intrinsic anti-tumor potential, particularly microglia. Understanding the single-cell spatial heterogeneity and interactions between immune cells and brain tumorâ€“initiating cells (BTICs) is essential for identifying therapeutic targets to reprogram immune responses and suppress BTIC growth. Using single-cell and spatial transcriptomics, we mapped immune cell populations in the GBM microenvironment and identified signaling networks mediating immuneâ€“cancer cell interactions. We discovered a previously unrecognized subset of microglia expressing protein kinase CÎ´ (PKCÎ´) with anti-tumor activity against BTICs. The presence of PKCÎ´-expressing microglia was validated in human GBM specimens. Enhancing PKCÎ´ in microglia via adeno-associated virus or niacin increased phagocytosis of patient-derived BTICs in vitro and improved survival in GBM-bearing mice. Data from The Cancer Genome Atlas (TCGA) revealed that high PKCÎ´ expression correlates with increased apoptosis, phagocytosis, and immune signaling pathways. These findings offer highlight PKCÎ´+ microglia as a promising therapeutic target in GBM.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298688" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE285952ï¼šå¯¹æ¥å—è¿‡ç»§æ€§pmel-1 Tç»†èƒæ²»ç–—æˆ–æœªæ²»ç–—çš„å°é¼ ï¼ˆæºå¸¦æ–°æŠ—åŸï¼ˆB16KVPï¼‰æˆ–é‡ç”Ÿå‹ï¼ˆB16F10ï¼‰è‚¿ç˜¤ï¼‰çš„è‚¿ç˜¤å’Œæ·‹å·´ç»“è¿›è¡ŒNanostringåˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€lymphã€T cellã€regex:lymph(o|atic)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Amalia Rivera Reyes ; Hannah M KnochelmannSeries Type : Expression profiling by arrayOrganism : Mus musculusTwo separate experiments were performed. Experiment 1: Mice were subcutaneously injected with either B16F10 or B16KVP tumors. 6 days later, they were given 5Gy total body irradiation as a lymphdepletion regimen. Then the next day, 500,000 naÃ¯ve pmel-1 CD8 T cells were injected via the tail vein into these mice. 5 days after adoptive cellular therapy, these mice were sacrified and the tumors and tumor draining lymph nodes harvested for Nanostring analysis. Experiment 2: Mice were subcutaneously injected with either B16F10 or B16KVP tumors. 6 days later, they were given 5Gy total body irradiation as a lymphdepletion regimen. Then the next day, mice were given no treatment or 500,000 naÃ¯ve pmel-1 CD8 T cells were injected via the tail vein into these mice. 5 days after adoptive cellular therapy, these mice were sacrified and the tumors harvested for Nanostring analysis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285952" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE307425 æŠ—ä½“é¶å‘åˆ†æ³Œè›‹ç™½ SCUBE3 é€šè¿‡æŠ‘åˆ¶ä¿ƒè‚¿ç˜¤ä¿¡å·ä¼ å¯¼å’Œè¯±å¯¼æŠ—è‚¿ç˜¤å…ç–«æ¥æŠ‘åˆ¶ç™Œç—‡ç”Ÿé•¿å’Œè½¬ç§»</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immunityã€antibody<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Deepika Singh ; Benjamin C Onyeagucha ; Manjeet Rao ; Zhao Lai ; Yidong ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThrough a loss-of-function genomic screening approach, we identified Signal peptide CUB domain EGF-like 3 (SCUBE3) as a critical player for the survival and therapy resistance of cancer cells, particularly in triple negative breast cancer (TNBC). To further understand the mechanism by which SCUBE3 may support tumor growth and metastasis, we performed gene expression analysis on MDA-MB-231 cells stably silenced for SCUBE3. Pathway analysis reveled that Myc signaling, G2M checkpoint and DNA repair-associated genes were highly downregulated, while IFN gamma, inflammatory response and immunity-associated pathways were highly upregulated in SCUBE3-silenced TNBC cells.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307425" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE302247 äºŒè‚½åŸºè‚½é…¶ 4 çš„æ¢å¤ä¿ƒè¿› KRAS-LKB1 çªå˜å‹è‚ºç™Œçš„æŠ—è‚¿ç˜¤å…ç–«</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immunityã€KRAS<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Toshiyuki Tenma ; Ryohei Yoshida ; Hiraku Yanada ; Kiichi Nitanai ; Toshihiro Nagato ; Kyohei Oyama ; Nobunari Sasaki ; Mizuki Homme ; Chie Mori ; Takayuki Ohkuri ; Yusuke Ono ; Shoichiro Tange ; Yoshinori Minami ; Hiroya Kobayashi ; Yusuke Mizukami ; David A Barbie ; Shunsuke Kitajima ; Takaaki SasakiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensKRAS proto-oncogene, GTPase (KRAS)-liver kinase B1 (LKB1)-mutant (KL) non-small cell lung cancer (NSCLC), characterized by a profoundly immunosuppressive tumor microenvironment (TME), is highly resistant to immune checkpoint inhibitors (ICIs). Despite their high tumor mutation burden, KL tumors exhibit low programmed cell death ligand 1 (PD-L1) expression, reduced immune cell infiltration, and suppressed immune signaling pathways. Through systematic genomic analyses, we found that LKB1 loss suppresses dipeptidyl peptidase 4 (DPP4) expression and activity in KRAS-mutant lung cancer. Therefore, we evaluated the therapeutic potential of restoring DPP4 function to improve the immune response in KL lung cancer using patient-derived tumor samples and syngeneic mouse models. Restoration of DPP4 expression reprogrammed the TME and significantly increased immune-related gene signatures, including those involved in T cell migration and natural killer (NK) cell activation. Indeed, DPP4 restoration in three-dimensional microfluidic models enhanced NK cell chemotaxis and activity in targeting tumor spheroids. Furthermore, DPP4 restoration in syngeneic KL murine models synergized with anti-PD-1 therapy to achieve significant tumor regression. These findings suggest that LKB1 loss suppresses DPP4 expression, contributing to the immunosuppressive characteristics of the TME in KL-NSCLC cells, whereas, restoring DPP4 expression promotes NK cell recruitment, facilitates immune activation, and enhances the effects of anti-PD-1 therapy. These results highlight DPP4 as a key immune modulator and a promising therapeutic target, offering a novel strategy to overcome immune resistance and enhance immunotherapy outcomes in this challenging subset of lung cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302247" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE309948 åˆ†æ³Œæ¿€é…¶ FAM20C è§¦å‘è„‚è‚ªç»†èƒåŠŸèƒ½éšœç¢ï¼Œä»è€Œå¯¼è‡´è‚¥èƒ–ä¸­çš„èƒ°å²›ç´ æŠµæŠ—å’Œç‚ç—‡</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammationã€kinaseã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusObesity is a major driver of type 2 diabetes (T2D) and related metabolic disorders, characterized by chronic inflammation and adipocyte dysfunction. However, the molecular triggers initiating these processes remain poorly understood. We identify FAM20C, a serine/threonine kinase, as an early obesity-induced mediator of adipocyte dysfunction. Fam20c expression is substantially upregulated in adipocytes in response to obesity, correlating with a proinflammatory transcriptional signature. Forced expression of Fam20c in adipocytes promotes robust upregulation of proinflammatory cytokines and induces insulin resistance that is dependent on its kinase activity. Conversely, deletion of adipocyte Fam20c after established obesity and hyperglycemia improves glucose tolerance, augments insulin sensitivity, and reduces visceral adiposity, without altering body weight. Phosphoproteomic studies reveal that FAM20C regulates phosphorylation of intracellular and secreted proteins, modulating pathways critical to inflammation, metabolism, and extracellular matrix remodeling. We identify FAM20C-dependent substrates, such as CNPY4, whose phosphorylation contributes to proinflammatory adipocyte signaling. Of translational relevance, we show that in humans visceral adipose FAM20C expression positively correlates with insulin resistance. Our findings establish FAM20C as an early regulator of obesity-induced adipocyte dysfunction and systemic metabolic impairment. Our studies provide proof of concept that inhibition of FAM20C may serve as a potential therapy for T2D by restoring adipocyte health.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309948" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE299929 ç ”ç©¶è¡¨æ˜ï¼Œæ³›ç»†èƒå‘¨æœŸè›‹ç™½ä¾èµ–æ€§æ¿€é…¶æŠ‘åˆ¶å‰‚æ˜¯ä¸€ç§æ½œåœ¨çš„è…ºæ ·å›Šæ€§ç™Œæ²»ç–—æ–¹æ³•ï¼Œå®ƒèƒ½ä¸‹è°ƒ MYB::NFIB èåˆåŸºå› å¹¶â€‹â€‹è¯±å¯¼è‚¿ç˜¤æ¶ˆé€€ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€kinase<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mattias K Andersson ; Junchi HuangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAdenoid cystic carcinoma (ACC) is a MYB-driven, aggressive glandular cancer with a poor long-term prognosis that is resistant to systemic therapies. Therefore, there is an urgent need to develop novel therapeutic strategies for these patients. An in vitro small-molecule inhibitor screen identified sensitivity of cultured ACC cells to pan-CDK inhibitors. We here used RNA-seq analysis to investigate the cell biological and molecular effects of treatment with the pan-CDK inhibitor dinaciclib in ACC cells from two different cases. Our results show that dinaciclib treatment led to a downregulation of genes involved in cell cycle progression, DNA replication, and DNA repair. Upregulated genes affected programmed cell death and included genes involved in proteolysis and autophagy. ACC MYB signature genes were significantly downregulated in dinaciclib-treated ACC cells, indicating that dinaciclib perturbs MYB-driven gene expression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299929" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE306418 è…¹ä¾§è§†ç½‘è†œçš„è¿›åŒ–é‡å¡‘ä½¿å››çœ¼é±¼ Anableps anableps å…·å¤‡ç©ºä¸­è§†è§‰ [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Louise N. Perez ; Josane de Freitas Sousa ; Patricia SchneiderSeries Type : OtherOrganism : Anableps anablepsThe emergence of evolutionary novelties remains a central challenge in biology, particularly forcomplex organs such as the vertebrate eye. While visual systems have repeatedly undergonedegeneration or loss, examples of innovation are rare and poorly understood. Mechanistic insight intosuch gains requires tractable systems in which novel visual functions have evolved. Here we leverage thefour-eyed fish Anableps anableps to uncover the cellular and molecular basis of adaptation tosimultaneous aerial and aquatic light. Combining single-nucleus and spatial transcriptomics, we show thatthe Anableps ventral retina has been developmentally and functionally reconfigured for aerial vision. Infully aquatic teleosts such as zebrafish, ventral photoreceptors are tuned to red-shifted, downwelling light.In contrast, we show that Anableps exhibits an expanded and diversified ventral cone populationencompassing ultraviolet-, blue-, green-, and red-sensitive types, enabling broad-spectrum, high-intensityvision from above water. To estimate Anableps opsin spectral properties, we employed OPTICS, amachine-learning model of opsin spectral tuning, which predicts that the ventrally expressed opn1mw2opsin is red-shifted relative to typical green-sensitive pigments. Analysis of dorsal-ventral patterningmarkers reveals an overrepresentation of ventral retinal cell types. Consistent with this, comparativespatial transcriptomic profiling of developing and adult Anableps and the killifish (Fundulus heteroclitus)indicates a dorsal displacement of the dorsal-ventral boundary in Anableps, resulting in a proportionallylarger ventral retinal domain. Collectively, our results reveal that Anableps achieved its unique dual visualcapacity by developmentally expanding and functionally reprogramming the ventral retina for aerial lightdetection, an evolutionary innovation that redefines how retinal domains can adapt to radically differentvisual environments.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306418" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE305510 æ•´åˆç½‘ç»œè¯ç†å­¦ã€è½¬å½•ç»„å­¦å’Œå•ç»†èƒæµ‹åºæŠ€æœ¯æ¢è®¨æŸ”è‚å…‹åŠ›ç¼“è§£è‚ç¡¬åŒ–çš„ä½œç”¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chengbo Jin ; Tianle Ma ; Yiheng Zhang ; Xujing Gu ; Tong Zhu ; Xinyu Wu ; Xin Ding ; Suzhou Huang ; Yulan Wang ; Zhipeng Chen ; Huihua Fang ; Li WuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground: The progression of liver cirrhosis leads to severe complications, significantly threatening the survival and prognosis of patients. Rou gan ke li (Rgkl), a herbal formula derived from classical prescriptions, has used clinically over two decades and has good efficacy. However, its molecular mechanisms and active components remain undefined. Purpose: Exploring the molecular mechanisms of Rgkl in alleviating liver cirrhosis. Methods: CCl4-induced liver cirrhosis mice models were established. Liver stiffness and intrahepatic blood flow velocity were assessed using imaging. Serum ALT, AST, HA, and histopathology were analyzed. Hepatic stellate cells (HSCs) activation, liver sinusoidal endothelial cells (LSECs) fenestration, and angiogenesis were evaluated using immunohistochemistry and scanning electron microscopy. UPLC-Q-TOF-MS/MS and network pharmacology identified active components. Transcriptomics and single-cell sequencing identified key targets and pathways, validated via WB, immunofluorescence, and molecular docking. Results: Rgkl significantly reduced Liver stiffness and collagen deposition while increasing intrahepatic blood flow velocity in cirrhotic mice. Serum ALT, AST, and HA were markedly decreased. Rgkl inhibited Î±-SMA expression in HSC and downregulated pathological angiogenesis by reducing VEGF and CD34 expression. Additionally, Rgkl enhanced eNOS expression and preserved sinusoidal fenestration in LSEC. Furthermore, Rgkl ameliorated liver cirrhosis by modulating LSEC metabolic functions via the CD36/PPAR/CPT-1 pathway and suppressing HSC activation through the RhoA/ROCK/YAP and PI3K/AKT/NF-ÎºB pathways. Eighteen active components, such as Levistilide A and Quercetin, were strongly correlated with the amelioration of liver cirrhosis. Conclusions: Rgkl significantly attenuated hepatic injury and fibrosis. Mechanistically, Rgkl modulated LSEC lipid metabolism and phenotypic regulation, and suppressed HSC contraction and activation. Key active components contributing to these effects included Paeonilactone C, Levistilide A, and Quercetin.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305510" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE288271 å†…æºæ€§é€†è½¬å½•ç—…æ¯’é€šè¿‡ RIG-I é€šè·¯ä¿ƒè¿›ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®ä¸­å¼‚å¸¸çš„ T ç»†èƒåˆ†åŒ– [å…¨è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šT cellã€transcriptomicsã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiaoli Min ; Yaqian Yu ; Zhi HuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe dysregulated differentiation of T lymphocytes play an important role in systemic lupus erythematosus (SLE). However, the underlying mechanism remains unclear. Here, we screened and identified many overexpressed HERVs in CD4+ T cells from SLE patients by whole transcriptome resequencing and found that some HERVs formed dsRNAs to induce the activation of the RIG-I signaling pathway. And our findings reveal the roles and mechanism of HERVs and RIG-I in regulating the aberrant differentiation of T cells in SLE patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288271" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 75 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (6æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨6æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>ç”± BMP2/4-ACVR1 ä¿¡å·ä»‹å¯¼çš„è‚¿ç˜¤å‰å·¨å™¬ç»†èƒæåŒ–ï¼Œåœ¨è‚¿ç˜¤èµ·å§‹è¿‡ç¨‹ä¸­è°ƒæ§å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€Bç»†èƒã€å·¨å™¬ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç™Œç»†èƒèƒ½å¤Ÿé€šè¿‡åˆ¶é€ å…ç–«æŠ‘åˆ¶æ€§çš„â€œå†·â€è‚¿ç˜¤å¾®ç¯å¢ƒï¼ˆcTMEï¼‰æ¥è§„é¿å…ç–«ç›‘æµ‹ã€‚æ›´å¥½åœ°ç†è§£è‚¿ç˜¤å½¢æˆåˆæœŸ cTME å»ºç«‹æœºåˆ¶ï¼Œæœ‰åŠ©äºæ­ç¤ºæ›´ä¼˜çš„å…ç–«æ²»ç–—ç­–ç•¥ã€‚ä¸ºè¡¨å¾ cTME å½¢æˆçš„æ—¶é—´åŠ¨æ€ï¼Œæˆ‘ä»¬åœ¨ EGFR é©±åŠ¨è‚ºè…ºç™Œï¼ˆLUADï¼‰èµ·å§‹é˜¶æ®µç”Ÿæˆäº†å•ç»†èƒ RNA æµ‹åºæ•°æ®ã€‚TME ä¸­çš„å·¨å™¬ç»†èƒç»å†äº†ä»æŠ—è‚¿ç˜¤å·¨å™¬ç»†èƒå‘å‰è‚¿ç˜¤å·¨å™¬ç»†èƒçš„çŠ¶æ€è½¬å˜ï¼Œè¿™ä¿ƒæˆäº† cTME çš„å½¢æˆã€‚è‚¿ç˜¤ç»†èƒæ¥æºçš„ BMP2/4 è¯±å¯¼äº†å‰è‚¿ç˜¤å·¨å™¬ç»†èƒçš„æåŒ–ï¼Œä½¿ç”¨ ACVR1 æŠ‘åˆ¶å‰‚æŠ‘åˆ¶ BMP2/4-ACVR1 è½´ï¼Œå°† cTME è½¬åŒ–ä¸ºâ€œçƒ­â€TMEï¼ˆhTMEï¼‰ï¼Œä»è€Œæœ‰æ•ˆæŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿ã€‚æ­¤å¤–ï¼ŒEGFR çªå˜ LUAD æ‚£è€…è¡¨ç°å‡ºä¸å°é¼ è§‚å¯Ÿåˆ°çš„ cTME ç›¸ä¼¼ç‰¹å¾ï¼ŒACVR1 è¡¨è¾¾é«˜ä¸æ‚£è€…é¢„åè¾ƒå·®ç›¸å…³ã€‚æ€»ä½“è€Œè¨€ï¼Œé™¤äº†é˜æ˜å‰è‚¿ç˜¤å·¨å™¬ç»†èƒåœ¨ cTME å½¢æˆä¸­çš„ä½œç”¨å¤–ï¼Œæœ¬ç ”ç©¶è¿˜æ˜ç¡®å°† ACVR1 ä½œä¸ºæ²»ç–— EGFR çªå˜è‚ºç™Œçš„æ²»ç–—ç­–ç•¥ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990852569088503808/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>åŒç‰¹å¼‚æ€§æŠ—ä½“ä¸çº³ç±³æŠ€æœ¯ï¼šç™Œç—‡å…ç–«æ²»ç–—ä¸­çš„æˆ˜ç•¥è”ç›Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«ã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: åŒç‰¹å¼‚æ€§æŠ—ä½“ï¼ˆbsAbï¼‰æ—¨åœ¨è¯†åˆ«ä¸¤ç§ä¸åŒçš„æŠ—åŸæˆ–è¡¨ä½ï¼Œä½¿æ–°ä¸€ä»£ç™Œç—‡å…ç–«ç–—æ³•èƒ½å¤Ÿåˆ›æ–°åœ°å‘æŒ¥ä½œç”¨æœºåˆ¶ã€‚å°½ç®¡å…·æœ‰æ½œåŠ›ï¼ŒbsAb æ²»ç–—è¯ç‰©ä»é¢ä¸´ç”Ÿç‰©åˆ†å¸ƒå’Œè¯ä»£åŠ¨åŠ›å­¦æ–¹é¢çš„è¯¸å¤šæŒ‘æˆ˜ï¼Œå¸¸å¸¸å¯¼è‡´ç–—æ•ˆä¸æ¯’æ€§å¹³è¡¡ä¸ä½³ã€‚æœ¬ç»¼è¿°ä»ç®€è¦ä»‹ç» bsAbs åœ¨ç™Œç—‡å…ç–«æ²»ç–—ä¸­çš„ç›¸å…³æ€§å¼€å§‹ï¼Œæ—¨åœ¨æ‰¹åˆ¤æ€§åˆ†æçº³ç±³æŠ€æœ¯ä¸ bsAb æŠ€æœ¯åœ¨æå‡æ²»ç–—æ•ˆç‡åŒæ—¶é™ä½æ¯’æ€§æ–¹é¢çš„ååŒæ½œåŠ›ã€‚è¿™ç§ååŒæ•ˆåº”å¯ä»¥é€šè¿‡å¤šç§ç­–ç•¥å®ç°ï¼šï¼ˆiï¼‰bsAbs å¯èƒ½ä½œä¸ºé¶å‘é…ä½“ï¼Œæ”¹å–„è¯ç‰©è½½è·çº³ç±³è½½ä½“çš„ç”Ÿç‰©åˆ†å¸ƒ;ï¼ˆiiï¼‰å°†æ²»ç–—æ€§ bsAbs æºå…¥çº³ç±³è½½ä½“ï¼Œå¯èƒ½è½»æ¾å…‹æœç”Ÿç‰©å±éšœï¼Œè¾¾åˆ°ç›®æ ‡;ä»¥åŠï¼ˆiiiï¼‰bsAb å¯ä»¥é€šè¿‡ç¼–ç  mRNA è½½ä½“çš„çº³ç±³è½½ä½“åœ¨ä½“å†…ç”Ÿæˆã€‚æœ¬ç»¼è¿°æ¢è®¨äº†è¿™äº›æ–°å…´é¢†åŸŸçš„æŒ‘æˆ˜ï¼Œå¹¶ä¸ºè¯¥æœ‰å‰æ™¯é¢†åŸŸçš„æœªæ¥æ–¹å‘æä¾›äº†è§è§£ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990847782355841024/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>CRISPR-Cas9 ç­›æŸ¥è¯†åˆ«èƒ°è…ºç™Œä¸­å¯¹ KRAS æŠ‘åˆ¶çš„è€è¯æœºåˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè€è¯ã€KRAS<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: é’ˆå¯¹å„ç§ KRAS çªå˜çš„ KRAS æŠ‘åˆ¶å‰‚ï¼ˆKRASiï¼‰å·²è¿›å…¥èƒ°è…ºç™Œä¸´åºŠè¯•éªŒã€‚å°½ç®¡åˆæ­¥ä¸´åºŠååº”æœ‰å¸Œæœ›ï¼Œå¤§å¤šæ•°æ‚£è€…å› å†…åœ¨æˆ–åå¤©æ€§è€è¯æ€§è€Œå¤å‘ã€‚å› æ­¤ï¼Œè”åˆæ²»ç–—å¯¹äºå»¶é•¿ KRAS é¶å‘ç–—æ³•çš„ç–—æ•ˆè‡³å…³é‡è¦ã€‚ä¸ºè¿›ä¸€æ­¥ç¡®å®š KRASi è€è¯æ€§çš„é—ä¼ æœºåˆ¶ï¼Œæˆ‘ä»¬åœ¨ KRASG12Dã€KRASG12Cã€KRASG12R å’Œ KRASQ61H çªå˜ PDAC ç»†èƒç³»ä¸­è¿›è¡Œäº† KRASi é”šå®šçš„ CRISPR-Cas9 åŠŸèƒ½ä¸§å¤±ç­›æŸ¥ï¼Œä½¿ç”¨å…­ä¸ª KRASiï¼Œä»¥è¯†åˆ«è°ƒèŠ‚å¯¹ KRAS æŠ‘åˆ¶æ•æ„Ÿæ€§çš„åŸºå› ã€‚é€šè¿‡è”åˆé¶å‘æŠ‘åˆ¶å‰‚ä¸ KRASiï¼ŒéªŒè¯äº†åŒ…æ‹¬ EGFRã€CK2ã€p110Î±å’Œ p110Î³ä»¥åŠ YAP åœ¨å†…çš„å¤šä¸ªç­›æŸ¥ç»“æœã€‚KRASQ61H çªå˜ PDAC ç»†èƒç³»å¯¹ KRAS çš„ç”Ÿå­˜ä¾èµ–æ€§æœ¬è´¨ä¸Šä½äºå…¶ä»– KRAS çªå˜äºšå‹ã€‚æ­¤å¤–ï¼ŒEGFR æŠ‘åˆ¶å‰‚å„æ´›æ›¿å°¼ä¸ RASï¼ˆONï¼‰å¤šé€‰æ‹©æ€§æŠ‘åˆ¶å‰‚ RMC-7977 åœ¨ KRASQ61H<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990852560473403392/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>çº¿ç²’ä½“è½¬ç§»æŒ½æ•‘å‘¼å¸ï¼Œæ”¯æŒå˜§å•¶çš„ç”Ÿç‰©åˆæˆå’Œè‚¿ç˜¤è¿›å±•</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€çº¿ç²’ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: çº¿ç²’ä½“ DNAï¼ˆmtDNAï¼‰ä¸¥é‡ç¼ºé™·çš„ç™Œç»†èƒå¯ä»¥é€šè¿‡æ°´å¹³çº¿ç²’ä½“è½¬ç§»ï¼ˆHMTï¼‰å¯¼å…¥çº¿ç²’ä½“ä»¥æ¢å¤å‘¼å¸ã€‚çº¿ç²’ä½“å‘¼å¸å¯¹äºäºŒæ°¢é£Ÿæ°§é…¸è„±æ°¢é…¶ï¼ˆDHODHï¼‰çš„æ´»æ€§è‡³å…³é‡è¦ï¼ŒDHODH æ˜¯ä¸€ç§æ¥è‡ªçº¿ç²’ä½“å†…è†œçš„é…¶ï¼Œå‚¬åŒ–æ–°ç”Ÿå˜§å•¶åˆæˆçš„ç¬¬å››æ­¥ã€‚æœ¬ç ”ç©¶ç ”ç©¶äº†å˜§å•¶æ–°ç”Ÿåˆæˆåœ¨é©±åŠ¨çº¿ç²’ä½“ DNA ç¼ºä¹ï¼ˆÏ0ï¼‰ç»†èƒè‚¿ç˜¤ç”Ÿé•¿ä¸­çš„ä½œç”¨ã€‚è™½ç„¶åœ¨å°é¼ ä½“å†…ç§»æ¤çš„Ï0 ç»†èƒå®¹æ˜“è·å¾—çº¿ç²’ä½“ DNAï¼Œä½†åœ¨é‡‡ç”¨æ›¿ä»£æ°§åŒ–é…¶ï¼ˆAOXï¼‰è½¬æŸ“çš„ç»†èƒä¸­ï¼Œè¿™ä¸€è¿‡ç¨‹è¢«å»¶è¿Ÿï¼ŒAOX ç»“åˆäº†çº¿ç²’ä½“å‘¼å¸å¤åˆä½“ III å’Œ IV çš„åŠŸèƒ½ã€‚Ï0 AOX ç»†èƒå…·æœ‰ç³–è§£ä½œç”¨ï¼Œä½†ä¿æŒæ­£å¸¸çš„ DHODH æ´»æ€§å’Œå˜§å•¶çš„äº§ç”Ÿã€‚åœ¨ä¸€ç»„è‚¿ç˜¤ç»†èƒä¸­ DHODH çš„ç¼ºå¤±å®Œå…¨é˜»æ–­æˆ–å»¶ç¼“è‚¿ç˜¤ç”Ÿé•¿ã€‚è¿™äº›ç§»æ¤çš„Ï0 ç»†èƒè¿…é€Ÿæ‹›å‹Ÿäº†å…ˆå¤©å…ç–«ç³»ç»Ÿä¸­ä¿ƒè¿›è‚¿ç˜¤/ç¨³å®šçš„ç»†èƒï¼ŒåŒ…æ‹¬è‚¿ç˜¤å‰ M2 å·¨å™¬ç»†èƒã€ä¸­æ€§ç²’ç»†èƒã€å—œé…¸æ€§ç²’ç»†èƒå’Œé—´å……è´¨é—´è´¨ç»†èƒï¼ˆMSCsï¼‰ã€‚Ï0 ç»†èƒåœ¨ç§»æ¤åæ—©æœŸæ‹›å‹Ÿäº† MSCsï¼Œè¿™äº›<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990852561190629376/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>å‚¬åŒ–æŠ‘åˆ¶ p300 ä¼˜å…ˆé’ˆå¯¹ IRF4 è‡´ç™Œæ´»æ€§å’Œå¤šå‘æ€§éª¨é«“ç˜¤è‚¿ç˜¤ç”Ÿé•¿</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: è‡´ç™Œè½¬å½•å› å­ï¼ˆTFï¼‰IRF4 æ˜¯ä¸€ç§ç›®å‰å°šæœªè¢«å®Œå…¨ç¡®å®šçš„æ™®éå¤šå‘æ€§éª¨é«“ç˜¤ï¼ˆMMï¼‰ä¾èµ–æ€§ã€‚é€šè¿‡è½¬å½•è°ƒæ§ç½‘ç»œï¼ˆTRNï¼‰å®šä½ï¼Œä¸€ç§æ— åå¤šç»„ç›®æ ‡è¯†åˆ«æ–¹æ³•ï¼Œæˆ‘ä»¬é‰´å®šå‡ºå…±æ¿€æ´»å‰‚èµ–æ°¨é…¸ä¹™é…°è½¬ç§»é…¶ï¼ˆKATï¼‰p300 ä½œä¸ºå…³é”®çš„ IRF4 ä¼™ä¼´ã€‚é€šè¿‡å®šé‡ç›¸äº’ä½œç”¨ç»„å›¾è°±éªŒè¯äº†è¿™ä¸€åå¥½å…³ç³»ï¼Œå‘ç° IRF4 æ˜¯ MM ç‰¹å¼‚æ€§ä¾èµ–æœ€ä¸°å¯Œçš„ï¼Œä¸”æ¯”å…¶ä»–è½¬å½•å› å­å¦‚ IKZF1/IKZF3 ä¸ p300 æ›´ä¸ºç´§å¯†å¤åˆã€‚ä¼˜åŒ–çš„ p300 èµ–æ°¨é…¸ä¹™é…°è½¬ç§»é…¶ï¼ˆKATï¼‰æŠ‘åˆ¶å‰‚ä½¿ IRF4 æ´»æ€§å’Œ MM å¢æ®–åœ¨ä½“å¤–å’Œä½“å†…å‡å¾—ä»¥æŠ‘åˆ¶ã€‚p300/CBP KAT æŠ‘åˆ¶ä¼˜å…ˆé’ˆå¯¹ MM ç»†èƒè€Œéæ­£å¸¸ç»†èƒï¼Œç‰¹å¼‚æ€§è°ƒèŠ‚ MM è½¬å½•ç»„ï¼Œä¸” p300 KAT æŠ‘åˆ¶å‰‚åœ¨è¾ƒä½æ°´å¹³ä¸‹æ›´å®Œå…¨æŠ‘åˆ¶ IRF4 æ´»æ€§ï¼Œç›¸è¾ƒäºç°æœ‰ p300/CBP æº´ç»“æ„åŸŸæŠ‘åˆ¶å‰‚ã€‚æ­¤å¤–ï¼Œç»“åˆ p300/CBP KAT æŠ‘åˆ¶å‰‚åŠæ²»ç–—æ–¹æ³•ï¼Œç»“åˆé’ˆå¯¹ MM è½¬å½•çš„æ­£äº¤æœºåˆ¶ï¼Œäº§ç”Ÿäº†ååŒæŠ—è‚¿ç˜¤æ•ˆåº”ã€‚è¿™äº›æ•°æ®å…±åŒæ¨åŠ¨äº†<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990852569776369664/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GRPR è¯±å¯¼çš„ FAM135A è¡¨è¾¾ä¿ƒè¿›å‰åˆ—è…ºç™Œçš„ç¥ç»å‘¨æµ¸æ¶¦</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç¥ç»<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç¥ç»å‘¨å›´æµ¸æ¶¦ï¼ˆPNIï¼‰æ˜¯å‰åˆ—è…ºç™Œï¼ˆPCaï¼‰è½¬ç§»çš„ç‹¬ç«‹ä¸è‰¯é¢„åæ ‡å¿—ç‰©ã€‚èƒƒæ³Œç´ é‡Šæ”¾è‚½å—ä½“ï¼ˆGRPRï¼‰é¶å‘å½±åƒå’Œæ²»ç–—å·²è¿›å…¥ä¸´åºŠè¯•éªŒé˜¶æ®µï¼Œå…¶åœ¨ PCa ç¥ç»å‘¨å›´ä¾µè¢­ä¸­çš„ä½œç”¨å°šä¸æ˜ç¡®ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬å‘ç°äº†åºåˆ—ç›¸ä¼¼åº¦ 135 çš„å®¶æ—æˆå‘˜ Aï¼ˆæˆå‘˜ Aï¼‰à¼ˆFAM135Aà¼‰a æ˜¾æ€§ PNI é©±åŠ¨ä½“ï¼Œåœ¨ PCa ä¸­è¢« GRPR æ¿€æ´»ã€‚é¦–å…ˆï¼ŒPNI-PCa ç»„ç»‡è¡¨ç°å‡ºæ›´é«˜çš„ç¥ç»æ´»æ€§é…ä½“-å—ä½“ç›¸äº’ä½œç”¨æ´»æ€§ï¼Œå…¶ä¸­ FAM135A æ˜¯ PNI ç»„ä¸­æœ€æ˜¾è‘—çš„æ ‡å¿—ã€‚éšåï¼Œä½“å¤–å®éªŒä½¿ç”¨ PCa ç»†èƒå…±åŸ¹å…»ç³»ç»Ÿï¼ˆåŒ…æ‹¬ AR é˜³æ€§ LNCaP å’Œ AR é˜´æ€§ DU145/PC3ï¼‰æ˜¾ç¤ºï¼Œæ¶ˆç­è‚¿ç˜¤æ¶æ€§è‚¿ç˜¤å’Œç¥ç»ä¾µè¢­ FAM135Aã€‚æ­¤å¤–ï¼Œä½“å†… PCa-åéª¨ç¥ç»ä¾µè¢­å°é¼ æ¨¡å‹æ˜¾ç¤º FAM135A æŠ‘åˆ¶èƒ½æ§åˆ¶è‚¿ç˜¤ç”Ÿé•¿å¹¶æ”¹å–„è¿åŠ¨åŠŸèƒ½ã€‚æœ‰è¶£çš„æ˜¯ï¼ŒFAM135A ç»†èƒæ ¸å¯Œé›†ï¼Œå…¶æ ¸æ˜“ä½ç”±è›‹ç™½è´¨ç»†èƒè´¨-æ ¸è½¬è¿è›‹ç™½ RAN ä»‹å¯¼ã€‚ä»æœºåˆ¶ä¸Šçœ‹ï¼ŒRNA-Seq<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990847783047901184/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>äºšé©¬é€Šèæ¯’æ¶²å±•ç°å‡ºå¯¹æŠ—ä¹³è…ºç™Œçš„æƒŠäººåŠŸæ•ˆ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists are turning venom, radioisotopes, engineered proteins, and AI into powerful new tools against cancer. From Amazonian scorpions yielding molecules that kill breast cancer cells as effectively as chemotherapy, to improved fibrin sealants and custom-grown bioactive factors, researchers are pushing biotechnology into uncharted territory. Parallel teams are advancing radiotheranostics that diagnose and destroy tumors with precision, while others forge experimental vaccines that train the immune system using hybrid dendritic cells.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251117095658.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>epigenetic</td>
<td>15</td>
</tr>
<tr>
<td>cancer</td>
<td>14</td>
</tr>
<tr>
<td>single-cell</td>
<td>10</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>10</td>
</tr>
<tr>
<td>tumor</td>
<td>9</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>8</td>
</tr>
<tr>
<td>kinase</td>
<td>7</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>6</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>6</td>
</tr>
<tr>
<td>Tç»†èƒ</td>
<td>6</td>
</tr>
<tr>
<td>T cell</td>
<td>6</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>6</td>
</tr>
<tr>
<td>immune</td>
<td>6</td>
</tr>
<tr>
<td>sequencing</td>
<td>6</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>5</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>5</td>
</tr>
<tr>
<td>åŸºå› ç»„</td>
<td>5</td>
</tr>
<tr>
<td>inflammation</td>
<td>4</td>
</tr>
<tr>
<td>metabolic</td>
<td>4</td>
</tr>
<tr>
<td>pathway</td>
<td>4</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (21æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248620&amp;idx=5&amp;sn=90da95e0f3913c43f8c0e7b194686398" target="_blank" rel="noopener noreferrer">é¡¶åˆŠé‡Œç¨‹ç¢‘çªç ´ï¼å“ˆä½›å›¢é˜Ÿç»˜ 170 ä¸‡ T ç»†èƒå›¾è°±ï¼Œç”Ÿä¿¡æ³¨é‡Šæœ‰äº† â€œé»„é‡‘æ ‡å°ºâ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247658657&amp;idx=2&amp;sn=94186d6748a363a9627a882e213d3e4f" target="_blank" rel="noopener noreferrer">è‚ é“å¾®ç”Ÿç‰©ç»„ä¸è‡ªé—­ç—‡çš„å…³è”ç¼ºä¹ç§‘å­¦ä¾æ® | Cell Pressç§‘å­¦æ–°é—»</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&amp;mid=2247540993&amp;idx=1&amp;sn=5e8ff9a87e006d4157230bb7bb3b484c" target="_blank" rel="noopener noreferrer">èµ‹èƒ½ä¸´åºŠç ”ç©¶ï¼šå•ç»†èƒæµ‹åºå…¥é—¨å¤§è®²å ‚</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI4MjY5ODI1Nw==&amp;mid=2247496736&amp;idx=1&amp;sn=6fe2f63e1e933071570e58a0e553b27b" target="_blank" rel="noopener noreferrer">å•ç»†èƒæµ‹åºå’Œæ·±åº¦å­¦ä¹ ç³»åˆ—äºŒï¼šdatasetçš„æ„å»ºå’Œç”¨é€”</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498506&amp;idx=1&amp;sn=df8d4ff334f64802da0a2912aa73f5d4" target="_blank" rel="noopener noreferrer">ç”Ÿä¿¡åˆ†æä¸€å®šè¦çœ‹ï¼PCAtoolsåŒ…ï¼Œä¸»æˆåˆ†åˆ†æä¸€é”®æå®šï¼Œè½»æ¾ç©è½¬åŸºå› è¡¨è¾¾æ•°æ®å¯è§†åŒ–ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495610&amp;idx=1&amp;sn=c365d9bf918bc975691b7e8c5e7892e6" target="_blank" rel="noopener noreferrer">å¤ç°äº†å‡ å¼ æ¼‚äº®çš„ç”Ÿä¿¡ç»„åˆå›¾ï¼Œç¤ºä¾‹æ•°æ®å’Œä»£ç éƒ½å¤‡å¥½äº†ï¼Œæ²¡é—®é¢˜ï¼Œéƒ½èƒ½è·‘é€š</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568962&amp;idx=2&amp;sn=e64360f3f5147bee1d15b202e61b6993" target="_blank" rel="noopener noreferrer">è®©ç™Œç»†èƒâ€œå†…è€—â€è‡³æ­»ï¼æ–°ç­–ç•¥æœ‰æœ›ç²¾å‡†æ¸…é™¤æ¶æ€§è‚¿ç˜¤</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568962&amp;idx=1&amp;sn=5b2b8fce5aafa421acfa26def90913ba" target="_blank" rel="noopener noreferrer">ç§‘å­¦å®¶å‘ç°èƒ½å‡é‡çš„ç»†èŒï¼è‡ªè¡Œç”Ÿäº§â€œå‡è‚¥è¯â€ï¼Œæœ‰æœ›æŠµå¾¡é«˜è„‚é¥®é£Ÿå±å®³</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547057&amp;idx=1&amp;sn=2a9d5d2ca495e5badef96d80eca2d251" target="_blank" rel="noopener noreferrer">ä»æ½œæ°´åˆ°åˆ†äº«ï¼šæˆ‘åœ¨ç”Ÿä¿¡ç¾¤é‡Œè¢«ç‚¹äº®çš„ä¸€ä¸ªæœˆ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507389&amp;idx=2&amp;sn=0337559b5194e3fc3dcbb8b5863b3219" target="_blank" rel="noopener noreferrer">Nature | é­å®¶ç³ç­‰æ­ç¤ºåŠ¨ç‰©ä»æµ·æ´‹èµ°å‘é™†åœ°çš„åŸºå› ç»„ç§˜å¯†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MTExNTkwNA==&amp;mid=2247573360&amp;idx=1&amp;sn=9e6cffd40f5feeb3162503e20cc86765" target="_blank" rel="noopener noreferrer">å¤§ä½¬æ˜¯æ€ä¹ˆç”¨TCGAæ•°æ®åšå…ç–«åˆ†æçš„ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248620&amp;idx=7&amp;sn=8c3b3511e60d88e9a3b8b46d11000687" target="_blank" rel="noopener noreferrer">Natureï¼šscWGS+scRNAè§£å¯†å…¨åŸºå› ç»„å€å¢çš„æ¼”åŒ–åŠ¨æ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248620&amp;idx=4&amp;sn=21d3fdb37841feedbdffeb2ebed65370" target="_blank" rel="noopener noreferrer">åˆ«å‚»äº†ï¼å¤šç»„å­¦åªåšå…³è”å’Œé€šè·¯ï¼Ÿè¿™æ³¢è¡€äºï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248620&amp;idx=2&amp;sn=2bbc5947030c3468c489d2b967a3d8e2" target="_blank" rel="noopener noreferrer">é¢„åˆ¶èœæœ€åº”è¯¥å‡ºç°åœ¨ç”Ÿä¿¡é¢†åŸŸ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1OTkyMTE4Mg==&amp;mid=2247488940&amp;idx=1&amp;sn=84f59eca845427584f788edc47e411ab" target="_blank" rel="noopener noreferrer">å¾€å¾€æ²¡æƒ³åˆ°ï¼Œèƒ°è…ºç‚ç«Ÿç„¶æ”¹å–„å…ç–«æ²»ç–—æ•ˆæœï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247658497&amp;idx=3&amp;sn=ef3ca291f782ccd30b173016537d2069" target="_blank" rel="noopener noreferrer">Mol Plantæœˆåº¦ä¸»ç¼–æ¨è | ä¸­å›½å†œå¤§ä¸æ¨æ—ç­‰æ­ç¤ºç»†èƒè†œå—ä½“å¤åˆä½“è°ƒæ§æ¤ç‰©æ—©æœŸé«˜æ¸©ä¿¡å·èµ·å§‹çš„åˆ†å­æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247658497&amp;idx=2&amp;sn=a38acc3754efafcec03f4ea2d010f93c" target="_blank" rel="noopener noreferrer">é«˜ç›Šå†›/ç‹å³°/å»–é›¯å©·/èµµé½/æ–¹å…†å…ƒç­‰Cancer Cellï¼šæ­ç¤ºç±»æ½˜æ°ç»†èƒè½¬åˆ†åŒ–é©±åŠ¨ç»“ç›´è‚ ç™Œå¯¹KRAS/EGFRåŒé¶æ²»ç–—è€è¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247658657&amp;idx=1&amp;sn=4b75ab2393ef4231e43fdf73bc317001" target="_blank" rel="noopener noreferrer">å¾®ç”Ÿç‰©ï¼šåœ°çƒå¥åº·çš„éšå½¢å®ˆæŠ¤è€… | Cell Press Live</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510197&amp;idx=4&amp;sn=dfb6e9b498b3d74e6ddacf0a5b9844fd" target="_blank" rel="noopener noreferrer">ä»£è°¢é‡ç¼–ç¨‹ï¼ä¸­å—å¤§å­¦æ¹˜é›…åŒ»é™¢/é¦™æ¸¯å¤§å­¦åˆä½œå‘æ–‡ï¼šæ²»ç–—è‚ºç™Œè„‘è½¬ç§»çš„ä¸€ç§æœ‰å‰æ™¯çš„ç­–ç•¥</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510197&amp;idx=3&amp;sn=c3c75fc964798b8a6d68633174c2d8f1" target="_blank" rel="noopener noreferrer">å“®å–˜å’Œæ…¢æ€§é¼»çª¦ç‚ä¼´é¼»æ¯è‚‰ä¸¤ç§ç–¾ç—…ä¸ºä½•ç»å¸¸åŒæ—¶å‡ºç°ï¼Ÿè¶…75ä¸‡äººåŸºå› ç»„æ•°æ®åˆ†æï¼Œå‘ç°71ä¸ªå…±äº«åŸºå› ä½ç‚¹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490041&amp;idx=1&amp;sn=4d6a26f8b8eea2ae75248d3c68de8ef3" target="_blank" rel="noopener noreferrer">åå¤§æŠ—è¡°è€ç‰©è´¨åŠå…¶ä½œç”¨æœºç†</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (75æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308299" target="_blank" rel="noopener noreferrer">GSE308299 ç ”ç©¶å‘ç°ï¼Œåœ¨åµå·¢ç™Œä¸´åºŠå‰æ¨¡å‹ä¸­ï¼ŒJNK æ•²ä½é€šè¿‡ NFATc1 å¢å¼º CAR-T ç»†èƒçš„ç»†èƒæ¯’æ€§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306569" target="_blank" rel="noopener noreferrer">GSE306569 çƒçŠ¶ä½“åŸ¹å…»æ­ç¤ºäº†ä¸‰é˜´æ€§ä¹³è…ºç™Œä¸­ç™Œç—‡å¹²ç»†èƒçš„å¯Œé›†å’Œç‹¬ç‰¹çš„åŒ–ç–—ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306950" target="_blank" rel="noopener noreferrer">GSE306950 NKç»†èƒæ´»åŒ–å¤±è°ƒå’Œé«“ç³»-æ·‹å·´ç³»å¤±è¡¡æ˜¯COPDè¿›å±•çš„åŸºç¡€ï¼šæ¥è‡ªé«˜ç»´å…ç–«åˆ†æå’Œå¸çƒŸè¯±å¯¼çš„å…ç–«é‡å¡‘çš„å¯ç¤º</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298464" target="_blank" rel="noopener noreferrer">GSE298464 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºæºƒç–¡æ€§ç»“è‚ ç‚æ‚£è€…å¯¹ TNF-Î± æŠ‘åˆ¶å‰‚æ²»ç–—çš„ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297006" target="_blank" rel="noopener noreferrer">GSE297006 å†…æºæ€§é€†è½¬å½•ç—…æ¯’é€šè¿‡ RIG-I é€šè·¯ä¿ƒè¿›ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®ä¸­å¼‚å¸¸çš„ T ç»†èƒåˆ†åŒ– [SLE]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296556" target="_blank" rel="noopener noreferrer">GSE296556 å†…æºæ€§é€†è½¬å½•ç—…æ¯’é€šè¿‡ RIG-I é€šè·¯ä¿ƒè¿›ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®ä¸­å¼‚å¸¸çš„ T ç»†èƒåˆ†åŒ– [mouse_CD4]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296447" target="_blank" rel="noopener noreferrer">GSE296447 ç‹¬ç‰¹çš„ç©ºé—´ç»„ç»‡è°ƒæ§å£è…”é»è†œå…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292853" target="_blank" rel="noopener noreferrer">GSE292853 Ribo-lite æ˜¯ä¸€ç§åœ¨ä½èµ·å§‹é‡ä¸‹å¯¹æ¥å— 5+3 æˆ–è½½ä½“æ²»ç–—å¹¶å–‚é£Ÿæ ‡å‡†æ°¨åŸºé…¸ (AA) æˆ–ä¸å«æ”¯é“¾æ°¨åŸºé…¸ (BCAA) é¥®é£Ÿçš„å°é¼  AML ç»†èƒè¿›è¡Œé…å¯¹è½¬å½•ç»„ (RNA-seq) å’Œç¿»è¯‘ç»„ (Ribo-seq) åˆ†æçš„æ–¹æ³•ã€‚[II]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288272" target="_blank" rel="noopener noreferrer">GSE288272 å†…æºæ€§é€†è½¬å½•ç—…æ¯’é€šè¿‡ RIG-I é€šè·¯ä¿ƒè¿›ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®ä¸­å¼‚å¸¸çš„ T ç»†èƒåˆ†åŒ– [å¹¼ç¨š]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283618" target="_blank" rel="noopener noreferrer">GSE283618 FSTL3 è¿‡è¡¨è¾¾æ˜¯è°ƒæ§åŒåŸºå› å°é¼ åµå·¢è‚¿ç˜¤å¾®ç¯å¢ƒçš„å…³é”®å› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280939" target="_blank" rel="noopener noreferrer">GSE280939 å‘ç°ä¸€ç§å°å°ºå¯¸å’ªå”‘-è‹¯å¹¶å²å“šé…ä½“ï¼Œè¯¥é…ä½“å¯ä¸ KRAS å¯åŠ¨å­ G-å››é“¾ä½“ç»“åˆï¼ŒæŠ‘åˆ¶ç™Œç—‡ç”Ÿé•¿å¹¶å¢å¼ºå…ç–«è°ƒèŠ‚ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266202" target="_blank" rel="noopener noreferrer">GSE266202 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ å˜åŒ–å¢åŠ é«˜ AID æ´»æ€§æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒä¸­çš„æ˜“ä½ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255082" target="_blank" rel="noopener noreferrer">GSE255082 é«˜è¡€å‹é€šè¿‡äº¤æ„Ÿç¥ç»æ¿€æ´»å¤–å‘¨å…ç–«ç³»ç»Ÿä¿ƒè¿›æµ·é©¬ç‚ç—‡å’Œè®¤çŸ¥éšœç¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231781" target="_blank" rel="noopener noreferrer">GSE231781 æ‚£è€…æ¥æºå®«é¢ˆç±»å™¨å®˜çš„å•ç»†èƒå›¾è°±æ­ç¤ºäº†è¡£åŸä½“æ„ŸæŸ“æœŸé—´ä¸Šçš®å…ç–«å¼‚è´¨æ€§å’Œç»†èƒé—´ç›¸äº’ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231775" target="_blank" rel="noopener noreferrer">GSE231775 æ‚£è€…æ¥æºå®«é¢ˆç±»å™¨å®˜çš„å•ç»†èƒå›¾è°±æ­ç¤ºäº†è¡£åŸä½“æ„ŸæŸ“æœŸé—´ä¸Šçš®å…ç–«å¼‚è´¨æ€§å’Œç»†èƒé—´ç›¸äº’ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231773" target="_blank" rel="noopener noreferrer">GSE231773 æ‚£è€…æ¥æºå®«é¢ˆç±»å™¨å®˜çš„å•ç»†èƒå›¾è°±æ­ç¤ºäº†è¡£åŸä½“æ„ŸæŸ“æœŸé—´ä¸Šçš®å…ç–«å¼‚è´¨æ€§å’Œç»†èƒé—´ç›¸äº’ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300915" target="_blank" rel="noopener noreferrer">GSE300915 éª¨å·¨å™¬ç»†èƒåå™¬ä½œç”¨è¯±å¯¼çš„ä»£è°¢è½¬å˜é©±åŠ¨ä¹³é…¸ç”Ÿæˆå¹¶è°ƒèŠ‚ç‚ç—‡å’Œç ´éª¨ç»†èƒç”Ÿæˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298405" target="_blank" rel="noopener noreferrer">GSE298405 åˆ©ç”¨ AAV9-ME CRISPR æ–‡åº“åœ¨å°é¼ è‚ºéƒ¨ç‚ç—‡æ¨¡å‹ä¸­ç­›é€‰å¿…éœ€ä»£è°¢ä»‹è´¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289642" target="_blank" rel="noopener noreferrer">GSE289642 éç»å…¸ PRC2 æŸ“è‰²è´¨å…³è”æ­ç¤º EZHIP åœ¨ä»£é™…è¡¨è§‚é—ä¼ è®°å¿†è½¬å˜ä¸­çš„å…³é”®ä½œç”¨ [ChIP-Seq, Cut &amp; Run]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289641" target="_blank" rel="noopener noreferrer">GSE289641 éç»å…¸ PRC2 æŸ“è‰²è´¨å…³è”æ­ç¤º EZHIP åœ¨ä»£é™…è¡¨è§‚é—ä¼ è®°å¿†è½¬å˜ä¸­çš„å…³é”®ä½œç”¨ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228743" target="_blank" rel="noopener noreferrer">GSE228743 HOXB13 é€šè¿‡ä¸ SWI/SNF å¤åˆç‰©çš„ç›¸äº’ä½œç”¨æ”¹å˜å‰åˆ—è…ºç™Œä¸­çš„æŸ“è‰²è´¨å¯åŠæ€§ [ChIP-seq ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228742" target="_blank" rel="noopener noreferrer">GSE228742 HOXB13 é€šè¿‡ä¸ SWI/SNF å¤åˆç‰©çš„ç›¸äº’ä½œç”¨æ”¹å˜å‰åˆ—è…ºç™Œä¸­çš„æŸ“è‰²è´¨å¯åŠæ€§ [ATAC-seq ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310403" target="_blank" rel="noopener noreferrer">GSE310403 æœè‡ yki è‚¿ç˜¤ç»„ç»‡ä¸¤ç§ç‰ˆæœ¬çš„ RNA æµ‹åºåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310343" target="_blank" rel="noopener noreferrer">GSE310343 IL-22 æ¥è‡ªè‚ å†…åˆ†æ³Œç»†èƒï¼Œé€šè¿‡å¾®ç”Ÿç‰©ç¾¤ä¿ƒè¿›æ–‘é©¬é±¼æ—©æœŸè‚ é“è •åŠ¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309795" target="_blank" rel="noopener noreferrer">GSE309795 é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚å¿ƒè„æ¯’æ€§çš„å¤šå°ºåº¦åˆ†ææ­ç¤ºæœºæ¢°æ•æ„Ÿç¦»å­é€šé“ PIEZO1 å…·æœ‰å¿ƒè„ä¿æŠ¤ä½œç”¨ [bulk RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297742" target="_blank" rel="noopener noreferrer">GSE297742 å‰åˆ—è…ºè…ºç™Œæ‚£è€…åŸå‘è‚¿ç˜¤æ´»æ£€æ ·æœ¬çš„æ‰¹é‡RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297652" target="_blank" rel="noopener noreferrer">GSE297652ï¼šM1æœŸå‰åˆ—è…ºç™Œæ‚£è€…è½¬ç§»ç¶æ´»æ£€å’Œå¤–å‘¨è¡€å•æ ¸ç»†èƒçš„å•ç»†èƒè½¬å½•ç»„è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310316" target="_blank" rel="noopener noreferrer">GSE310316 Nox4æŠ‘åˆ¶å‰‚æ²»ç–—å¯æ”¹å–„æœæ°è‚Œè¥å…»ä¸è‰¯ç—‡å°é¼ æ¨¡å‹çš„å¿ƒè„åŠŸèƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310057" target="_blank" rel="noopener noreferrer">GSE310057 å¯¹ RiboCancer ç»†èƒç³»é¢æ¿çš„ç¿»è¯‘ç»„å’Œç¿»è¯‘åŠ¨åŠ›å­¦åˆ†æè¡¨æ˜ï¼Œç™½è¡€ç—…ç›¸å…³çš„ Rps15 çªå˜é€šè¿‡å¯†ç å­ç‰¹å¼‚æ€§ tRNA é€‚åº”ç¼ºé™·é‡å¡‘ç¿»è¯‘ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251803" target="_blank" rel="noopener noreferrer">GSE251803 è½¬å½•å› å­ PLT å’ŒæŸ“è‰²è´¨è°ƒèŠ‚å› å­ PRC2 å’Œ JMJ703 å½¢æˆæ ¸å‡èšä½“ï¼Œä»¥ç»´æŒæ§åˆ¶æ°´ç¨»æ ¹åˆ†ç”Ÿç»„ç»‡ç»†èƒå‘½è¿çš„äºŒä»·ç»“æ„åŸŸä¸­çš„åŸºå› æŠ‘åˆ¶ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310346" target="_blank" rel="noopener noreferrer">GSE310346 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ æ”¹å˜å¢åŠ é«˜ AID æ´»æ€§æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒä¸­çš„æ˜“ä½ [MEC-1 ç»†èƒçš„ LAM-HTGTS ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310332" target="_blank" rel="noopener noreferrer">GSE310332 EVT0185 å¯¹ä¹™é…°è¾…é…¶Aä»£è°¢é…¶çš„æŠ‘åˆ¶ä½œç”¨å¯æŸå®³è‚æ˜ŸçŠ¶ç»†èƒæ´»åŒ–ï¼Œå¹¶é€†è½¬å°é¼ æ¨¡å‹ä¸­çš„MASHå’Œçº¤ç»´åŒ–[nanostring]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304764" target="_blank" rel="noopener noreferrer">GSE304764 æ¯ä½“è¡¥å……è›‹æ°¨é…¸è¯±å¯¼ç»µç¾Šåµæ¯ç»†èƒå’Œèƒšèƒçš„è¡¨è§‚é—ä¼ é‡å¡‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303874" target="_blank" rel="noopener noreferrer">GSE303874 æ²³å£æµ·è±šè„‘ç»„ç»‡RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302875" target="_blank" rel="noopener noreferrer">GSE302875 AngII åŠ ç›è¯±å¯¼çš„å°é¼ è…¹ä¸»åŠ¨è„‰ç˜¤çš„å•ç»†èƒè½¬å½•ç»„å­¦ç ”ç©¶[28 å¤©]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299152" target="_blank" rel="noopener noreferrer">GSE299152 æˆäººå’Œå°é¼ çœ¼è¡¨ç³–è¼çš„å•ç»†èƒå®šä½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298041" target="_blank" rel="noopener noreferrer">GSE298041 è‚ºä¸Šçš®æŸä¼¤æŸå®³å…ˆå¤©é˜²å¾¡å¹¶é‡ç¼–ç¨‹å·¨å™¬ç»†èƒåŠŸèƒ½ï¼Œé™ä½æ—©æœŸç»“æ ¸åˆ†ææ†èŒæ¸…é™¤ç‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297736" target="_blank" rel="noopener noreferrer">GSE297736 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ å˜åŒ–å¢åŠ é«˜ AID æ´»æ€§æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒä¸­çš„æ˜“ä½ [MEC-1 ä¸­çš„ HTGTS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296068" target="_blank" rel="noopener noreferrer">GSE296068 ä½è¾“å…¥é‡è½¬åº§é…¶å¯åŠæŸ“è‰²è´¨æ£€æµ‹æ–¹æ³•é‰´å®šè‚è„ 1 ç»„å›ºæœ‰æ·‹å·´ç»†èƒçš„è¡¨è§‚é—ä¼ ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295455" target="_blank" rel="noopener noreferrer">GSE295455 ä½“å¤–é‡‘é»„è‰²è‘¡è„çƒèŒåˆºæ¿€ç»µç¾Šä¹³è…ºä¸Šçš®ç»†èƒçš„é«˜é€šé‡è½¬å½•ç»„å­¦åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294437" target="_blank" rel="noopener noreferrer">GSE294437 HERV-K10 ä½œä¸ºè‚ç‚æ„ŸæŸ“ä¸­å…ç–«è°ƒèŠ‚çš„ä»‹è´¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293984" target="_blank" rel="noopener noreferrer">GSE293984 è¿æ¥çº¤æ¯›ã€åº”æ¿€ååº”å’Œè›‹ç™½è´¨ç¨³æ€å¼‚å¸¸ï¼Œä¸º RPGRIP1 è§†ç½‘è†œç±»å™¨å®˜çš„å˜å¼‚å’Œæ²»ç–—è¯„ä¼°æä¾›ä¿¡æ¯ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293982" target="_blank" rel="noopener noreferrer">GSE293982 è¿æ¥çº¤æ¯›ã€åº”æ¿€ååº”å’Œè›‹ç™½è´¨ç¨³æ€å¼‚å¸¸ï¼Œä¸º RPGRIP1 è§†ç½‘è†œç±»å™¨å®˜çš„å˜å¼‚å’Œæ²»ç–—è¯„ä¼°æä¾›ä¿¡æ¯ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292171" target="_blank" rel="noopener noreferrer">GSE292171 ç”¨æˆ–ä¸ç”¨ MLN4924 å¤„ç†çš„å·¨å™¬ç»†èƒçš„ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290428" target="_blank" rel="noopener noreferrer">GSE290428 æ—©æœŸé¥¥é¥¿å’Œ Hedgehog ç›¸å…³ä¿¡å·æ¿€æ´» daf-18/PTEN å’Œ lin-35/Rb ä¸‹æ¸¸çš„å…ˆå¤©å…ç–«ï¼Œå¯¼è‡´æˆå¹´ç§€ä¸½éšæ†çº¿è™«å‘è‚²ç—…ç†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290063" target="_blank" rel="noopener noreferrer">GSE290063 ç•ªèŒ„æœå®é‡‡åç»UV-Cç…§å°„åçš„è½¬å½•ç»„å’Œè¡¨è§‚é—ä¼ ç‰¹å¾ä¸æœå®å“è´¨çš„ä¿æŒç›¸å…³</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286009" target="_blank" rel="noopener noreferrer">GSE286009 MFF æ ‡å¿—ç€å¤šå‘æ€§éª¨é«“ç˜¤çš„ä»£è°¢è„†å¼±æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284296" target="_blank" rel="noopener noreferrer">GSE284296 èƒ¶è´¨ç˜¤ç»†èƒç³» LN229 å’Œ U87 ä¸­ç³–RNAçš„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282762" target="_blank" rel="noopener noreferrer">GSE282762 è¡¨è§‚åŸºå› ç»„æ“ä½œæ­ç¤ºäº†ä½ç‚¹ç‰¹å¼‚æ€§æŸ“è‰²è´¨åŠ¨æ€ä¸åŸºå› è¡¨è¾¾ä¹‹é—´çš„å…³ç³» [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282761" target="_blank" rel="noopener noreferrer">GSE282761 è¡¨è§‚åŸºå› ç»„æ“ä½œæ­ç¤ºäº†ä½ç‚¹ç‰¹å¼‚æ€§æŸ“è‰²è´¨åŠ¨æ€ä¸åŸºå› è¡¨è¾¾ä¹‹é—´çš„å…³ç³» [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282760" target="_blank" rel="noopener noreferrer">GSE282760 è¡¨è§‚åŸºå› ç»„æ“ä½œæ­ç¤ºäº†ä½ç‚¹ç‰¹å¼‚æ€§æŸ“è‰²è´¨åŠ¨æ€ä¸åŸºå› è¡¨è¾¾ä¹‹é—´çš„å…³ç³» [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282486" target="_blank" rel="noopener noreferrer">GSE282486 æœ‰ä¸åˆ†è£‚æœŸ Polo æ ·æ¿€é…¶ 1 çš„æ‰¹é‡ ATACseq åˆ†æè¡¨æ˜ï¼Œæœ‰ä¸åˆ†è£‚æœŸè½¬å½•å’ŒæŸ“è‰²ä½“å¯åŠæ€§å¾—ä»¥ç»´æŒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267993" target="_blank" rel="noopener noreferrer">GSE267993 ZNHIT3 è°ƒæ§ç¿»è¯‘ä»¥ç¡®ä¿å°é¼ æ¤å…¥å‰å‘è‚² [scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266298" target="_blank" rel="noopener noreferrer">GSE266298 EZH2æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ æ”¹å˜ä¼šå¢åŠ AIDæ´»æ€§é«˜æˆ–DNAä¿®å¤ç¼ºé™·çš„Bç»†èƒçš„æ˜“ä½ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266270" target="_blank" rel="noopener noreferrer">GSE266270 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ å˜åŒ–å¢åŠ é«˜ AID æ´»æ€§æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒä¸­çš„æ˜“ä½ [GRO-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266267" target="_blank" rel="noopener noreferrer">GSE266267 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ æ”¹å˜ä¼šå¢åŠ  AID æ´»æ€§é«˜æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒçš„æ˜“ä½ [H3K27ac çš„åˆ‡å‰²å’Œæ ‡è®°]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266237" target="_blank" rel="noopener noreferrer">GSE266237 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ æ”¹å˜ä¼šå¢åŠ é«˜ AID æ´»æ€§æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒä¸­çš„æ˜“ä½ [LAM-HTGTS for CH12F3 cell]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266205" target="_blank" rel="noopener noreferrer">GSE266205 EZH2 æŠ‘åˆ¶å¼•èµ·çš„è¡¨è§‚é—ä¼ æ”¹å˜ä¼šå¢åŠ é«˜ AID æ´»æ€§æˆ– DNA ä¿®å¤ç¼ºé™·çš„ B ç»†èƒä¸­çš„æ˜“ä½ [H3K27me3 çš„åˆ‡å‰²å’Œæ ‡è®°]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261167" target="_blank" rel="noopener noreferrer">GSE261167 ç»†èŒRNAé€šè¿‡ç§€ä¸½éšæ†çº¿è™«çš„ç»„ç»‡é—´é€šè®¯ä¿ƒè¿›è›‹ç™½è´¨ç¨³æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310263" target="_blank" rel="noopener noreferrer">GSE310263 mRNA N6-ç”²åŸºè…ºè‹· (m6A) åœ¨é«˜ L-2-ç¾ŸåŸºæˆŠäºŒé…¸è‚¾ç™Œä¸­çš„ç”Ÿç‰©å­¦ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309870" target="_blank" rel="noopener noreferrer">GSE309870 APOBEC3B å¢å¼º PARP æŠ‘åˆ¶å‰‚æ¸…é™¤åµå·¢ç™Œå¹²ç»†èƒçš„ç–—æ•ˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300925" target="_blank" rel="noopener noreferrer">GSE300925 å·¨å™¬ç»†èƒä¸­ Lyn çš„è¡¨è¾¾ä¿ƒè¿› TLR æ¿€æ´»å¹¶ä»¥ä¸€ç§ä¸ä¾èµ–äºäºšå‹çš„æ–¹å¼é™åˆ¶å¢æ®–ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297645" target="_blank" rel="noopener noreferrer">GSE297645 å°åˆ†å­ ITK å’Œæ³› TRK æ¿€é…¶æŠ‘åˆ¶å‰‚ (PF-07245303) ç”¨äºç‰¹åº”æ€§çš®ç‚çš„æ½œåœ¨å±€éƒ¨æ²»ç–—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289282" target="_blank" rel="noopener noreferrer">GSE289282 éç»å…¸ PRC2 æŸ“è‰²è´¨å…³è”æ­ç¤º EZHIP åœ¨ä»£é™…è¡¨è§‚é—ä¼ è®°å¿†è½¬æ¢ä¸­çš„å…³é”®ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273480" target="_blank" rel="noopener noreferrer">GSE273480 lncRNA CISTR-ACT è°ƒæ§äººå’Œå°é¼ çš„ç»†èƒå¤§å° [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273476" target="_blank" rel="noopener noreferrer">GSE273476 lncRNA CISTR-ACT è°ƒæ§äººå’Œå°é¼ çš„ç»†èƒå¤§å° [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE253048" target="_blank" rel="noopener noreferrer">GSE253048 ç¬¬11å¤©å¯¹ç…§ç»„ã€å…‰å­å’Œè´¨å­ç…§å°„ç»„å”¾æ¶²è…ºç±»å™¨å®˜çš„å•ç»†èƒæµ‹åºåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE253034" target="_blank" rel="noopener noreferrer">GSE253034 RNAæµ‹åºåˆ†æå¯¹ç…§ç»„ã€å…‰å­å’Œè´¨å­ç…§å°„ç»„å”¾æ¶²è…ºç±»å™¨å®˜åœ¨ç…§å°„å2å¤©å’Œ6å¤©çš„æƒ…å†µ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252164" target="_blank" rel="noopener noreferrer">GSE252164 ä¸»åŠ¨è„‰ç“£åæµå¾®åˆ›æ‰‹æœ¯åå¿ƒè„é‡å¡‘çš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310282" target="_blank" rel="noopener noreferrer">GSE310282 ç»“è‚ ä¸Šçš®å’Œå›ºæœ‰å±‚æ¥æºçš„ Treg çš„ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310225" target="_blank" rel="noopener noreferrer">GSE310225 ç²¾ç»†åŒ–çš„ç»†èƒæ´»æ€§è¡¨è¾¾ç‰¹å¾ä¸ºé‡åŒ–å•ç»†èƒæ•°æ®ä¸­çš„è‚¿ç˜¤å†…è¡¨å‹å¼‚è´¨æ€§æä¾›äº†ä¸€ä¸ªé¶å‘æ¡†æ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309878" target="_blank" rel="noopener noreferrer">GSE309878 ç¥ç»å‘è‚²éšœç¢æ‚£è€…ä¸­è¡¨è§‚é—ä¼ è°ƒæ§å› å­ PHF20 çš„çº¯åˆç¼ºå¤±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309861" target="_blank" rel="noopener noreferrer">GSE309861 KLF5 æ§åˆ¶èƒ°è…ºç™Œä¸­ä¸äºšå‹æ— å…³çš„é«˜ç›¸äº’ä½œç”¨å¢å¼ºå­ä»¥è°ƒèŠ‚ç»†èƒå­˜æ´» [HiChIPseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309860" target="_blank" rel="noopener noreferrer">GSE309860 KLF5 æ§åˆ¶èƒ°è…ºç™Œä¸­ä¸äºšå‹æ— å…³çš„é«˜ç›¸äº’ä½œç”¨å¢å¼ºå­ä»¥è°ƒèŠ‚ç»†èƒå­˜æ´» [ChIPseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299636" target="_blank" rel="noopener noreferrer">GSE299636 WDR5 é‡å¡‘ NANOG å‡èšä½“ä»¥é©±åŠ¨è½¬å½•ç¨‹åºå¹¶ç»´æŒå¹²ç»†èƒç‰¹æ€§ [ChIP-seq]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-19 21:36</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>